DUBLIN, Ireland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has adopted a negative opinion on the marketing authorization for natalizumab as a treatment for Crohn’s disease. This decision is on the appeal the companies filed following a previous negative opinion adopted by the CHMP earlier in 2007.
